Summary | |
---|---|
Symbol | NLK |
Name | nemo-like kinase |
Aliases | nemo like kinase; Protein LAK1; Serine/threonine-protein kinase NLK |
Chromosomal Location | 17q11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Nucleus Cytoplasm Note=Predominantly nuclear. A smaller fraction is cytoplasmic (By similarity). |
Domain |
PF00069 Protein kinase domain |
Function |
Serine/threonine-protein kinase that regulates a number of transcription factors with key roles in cell fate determination. Positive effector of the non-canonical Wnt signaling pathway, acting downstream of WNT5A, MAP3K7/TAK1 and HIPK2. Activation of this pathway causes binding to and phosphorylation of the histone methyltransferase SETDB1. The NLK-SETDB1 complex subsequently interacts with PPARG, leading to methylation of PPARG target promoters at histone H3K9 and transcriptional silencing. The resulting loss of PPARG target gene transcription inhibits adipogenesis and promotes osteoblastogenesis in mesenchymal stem cells (MSCs). Negative regulator of the canonical Wnt/beta-catenin signaling pathway. Binds to and phosphorylates TCF7L2/TCF4 and LEF1, promoting the dissociation of the TCF7L2/LEF1/beta-catenin complex from DNA, as well as the ubiquitination and subsequent proteolysis of LEF1. Together these effects inhibit the transcriptional activation of canonical Wnt/beta-catenin target genes. Negative regulator of the Notch signaling pathway. Binds to and phosphorylates NOTCH1, thereby preventing the formation of a transcriptionally active ternary complex of NOTCH1, RBPJ/RBPSUH and MAML1. Negative regulator of the MYB family of transcription factors. Phosphorylation of MYB leads to its subsequent proteolysis while phosphorylation of MYBL1 and MYBL2 inhibits their interaction with the coactivator CREBBP. Other transcription factors may also be inhibited by direct phosphorylation of CREBBP itself. Acts downstream of IL6 and MAP3K7/TAK1 to phosphorylate STAT3, which is in turn required for activation of NLK by MAP3K7/TAK1. Upon IL1B stimulus, cooperates with ATF5 to activate the transactivation activity of C/EBP subfamily members. Phosphorylates ATF5 but also stabilizes ATF5 protein levels in a kinase-independent manner (PubMed:25512613). |
Biological Process |
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway GO:0007179 transforming growth factor beta receptor signaling pathway GO:0007223 Wnt signaling pathway, calcium modulating pathway GO:0016055 Wnt signaling pathway GO:0018105 peptidyl-serine phosphorylation GO:0018107 peptidyl-threonine phosphorylation GO:0018209 peptidyl-serine modification GO:0018210 peptidyl-threonine modification GO:0030111 regulation of Wnt signaling pathway GO:0030178 negative regulation of Wnt signaling pathway GO:0031647 regulation of protein stability GO:0033136 serine phosphorylation of STAT3 protein GO:0035567 non-canonical Wnt signaling pathway GO:0042501 serine phosphorylation of STAT protein GO:0046425 regulation of JAK-STAT cascade GO:0046777 protein autophosphorylation GO:0050821 protein stabilization GO:0071559 response to transforming growth factor beta GO:0071560 cellular response to transforming growth factor beta stimulus GO:0198738 cell-cell signaling by wnt GO:1904892 regulation of STAT cascade |
Molecular Function |
GO:0000287 magnesium ion binding GO:0004674 protein serine/threonine kinase activity GO:0004702 receptor signaling protein serine/threonine kinase activity GO:0004707 MAP kinase activity GO:0005057 receptor signaling protein activity GO:0008134 transcription factor binding GO:0031625 ubiquitin protein ligase binding GO:0042169 SH2 domain binding GO:0044389 ubiquitin-like protein ligase binding |
Cellular Component | - |
KEGG |
hsa04010 MAPK signaling pathway hsa04068 FoxO signaling pathway hsa04310 Wnt signaling pathway hsa04520 Adherens junction |
Reactome |
R-HSA-3858494: Beta-catenin independent WNT signaling R-HSA-4086398: Ca2+ pathway R-HSA-162582: Signal Transduction R-HSA-195721: Signaling by Wnt |
Summary | |
---|---|
Symbol | NLK |
Name | nemo-like kinase |
Aliases | nemo like kinase; Protein LAK1; Serine/threonine-protein kinase NLK |
Chromosomal Location | 17q11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between NLK and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | NLK |
Name | nemo-like kinase |
Aliases | nemo like kinase; Protein LAK1; Serine/threonine-protein kinase NLK |
Chromosomal Location | 17q11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of NLK in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | NLK |
Name | nemo-like kinase |
Aliases | nemo like kinase; Protein LAK1; Serine/threonine-protein kinase NLK |
Chromosomal Location | 17q11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of NLK in various data sets.
|
There is no record. |
Summary | |
---|---|
Symbol | NLK |
Name | nemo-like kinase |
Aliases | nemo like kinase; Protein LAK1; Serine/threonine-protein kinase NLK |
Chromosomal Location | 17q11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NLK. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | NLK |
Name | nemo-like kinase |
Aliases | nemo like kinase; Protein LAK1; Serine/threonine-protein kinase NLK |
Chromosomal Location | 17q11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NLK. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NLK. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | NLK |
Name | nemo-like kinase |
Aliases | nemo like kinase; Protein LAK1; Serine/threonine-protein kinase NLK |
Chromosomal Location | 17q11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NLK. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | NLK |
Name | nemo-like kinase |
Aliases | nemo like kinase; Protein LAK1; Serine/threonine-protein kinase NLK |
Chromosomal Location | 17q11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of NLK expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | NLK |
Name | nemo-like kinase |
Aliases | nemo like kinase; Protein LAK1; Serine/threonine-protein kinase NLK |
Chromosomal Location | 17q11.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between NLK and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |